A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms MOUNTAINEER
- 11 Sep 2017 According to a Cascadian Therapeutics media release, data from this study were presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
- 13 Jun 2017 Planned End Date changed from 31 Mar 2019 to 30 Jun 2020.
- 13 Jun 2017 Planned primary completion date changed from 30 Sep 2018 to 30 Jun 2019.